Tvardi Therapeutics Inc (NASDAQ: TVRD)’s stock price has soared by 17.95 in relation to previous closing price of 27.74. Nevertheless, the company has seen a gain of 24.17% in its stock price over the last five trading days. businesswire.com reported 2025-05-20 that HOUSTON–(BUSINESS WIRE)– #IdiopathicPulmonaryFibrosis–Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company’s Management will participate in the Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways, being held Tuesday, May 27, 2025, and the Jefferies Global Healthcare Conference, being held June 3 – 5, 2025, in New Yor.
Is It Worth Investing in Tvardi Therapeutics Inc (NASDAQ: TVRD) Right Now?
TVRD has 36-month beta value of 0.24. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TVRD is 7.12M, and currently, short sellers hold a 0.13% ratio of that float. The average trading volume of TVRD on May 22, 2025 was 18.91K shares.
TVRD’s Market Performance
TVRD stock saw an increase of 24.17% in the past week, with a monthly gain of 67.88% and a quarterly increase of 117.26%. The volatility ratio for the week is 11.49%, and the volatility levels for the last 30 days are 11.85% for Tvardi Therapeutics Inc (TVRD). The simple moving average for the past 20 days is 29.06% for TVRD’s stock, with a 131.96% simple moving average for the past 200 days.
Analysts’ Opinion of TVRD
BTIG Research, on the other hand, stated in their research note that they expect to see TVRD reach a price target of $55. The rating they have provided for TVRD stocks is “Buy” according to the report published on May 15th, 2025.
Stifel gave a rating of “Hold” to TVRD, setting the target price at $1 in the report published on June 13th of the previous year.
TVRD Trading at 66.52% from the 50-Day Moving Average
After a stumble in the market that brought TVRD to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 12.29% of gains for the given period.
Volatility was left at 11.85%, however, over the last 30 days, the volatility rate increased by 11.49%, as shares surge +77.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +112.81% upper at present.
During the last 5 trading sessions, TVRD rose by +24.17%, which changed the moving average for the period of 200-days by +162.68% in comparison to the 20-day moving average, which settled at $25.35. In addition, Tvardi Therapeutics Inc saw 78.21% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TVRD starting from Posner Christopher, who sale 583 shares at the price of $4.75 back on Feb 28 ’25. After this action, Posner Christopher now owns 13,109 shares of Tvardi Therapeutics Inc, valued at $2,769 using the latest closing price.
Terrillion Scott, the SEC’Y; CHIEF COMPLIANCE & G.C. of Tvardi Therapeutics Inc, sale 163 shares at $4.76 during a trade that took place back on Feb 28 ’25, which means that Terrillion Scott is holding 7,190 shares at $776 based on the most recent closing price.
Stock Fundamentals for TVRD
The total capital return value is set at -0.79. Equity return is now at value -270.01, with -83.53 for asset returns.
Based on Tvardi Therapeutics Inc (TVRD), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -57.17.
Currently, EBITDA for the company is -17.25 million with net debt to EBITDA at 1.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.03.
Conclusion
To put it simply, Tvardi Therapeutics Inc (TVRD) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
